Background Patients hospitalized with COVID-19 often exhibit markers of a hypercoagulable
state and have an increased incidence of VTE. In response, CHEST issued rapid clinical …

Critically ill patients with COVID-19 are at increased risk for thrombotic complications which
has led to an intense debate surrounding their anticoagulation management. In the absence …

Coronavirus disease 2019 (COVID‐19) is associated with a hypercoagulable state. It has
been hypothesized that higher‐dose anticoagulation, including therapeutic‐dose and …

Objective Infection with the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)
virus confers a risk of significant coagulopathy, with the resulting development of venous …

Background Patients with COVID-19 infection are commonly reported to have an increased
risk of venous thrombosis. The choice of anti-thrombotic agents and doses are currently …

A prothrombotic state is reported with severe COVID-19 infection, which can manifest in
venous and arterial thrombotic events. Coagulopathy is reflective of more severe disease …

Growing evidence from multiple retrospective cohorts indicates that hospitalised COVID-19
patients often could suffer from an excessive coagulation activation leading to an increased …

Hypercoagulability is an increasingly recognized complication of SARS‐CoV‐2 infection. As
such, anticoagulation has become part and parcel of comprehensive COVID‐19 …

Importance COVID-19 is associated with a high incidence of thrombotic events; however, the
need for extended thromboprophylaxis after hospitalization remains unclear. Objective To …

Background Antithrombotic guidance statements for hospitalized patients with coronavirus
disease 2019 (COVID‐19) suggest a universal thromboprophylactic strategy with potential to …